Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use

• US 7,883,698 B2
• Filed: 01/17/2007
• Issued: 02/08/2011
• Est. Priority Date: 01/17/2007
• Status: Expired due to Fees

• Current Assignee: Maria Michejda
• Original Assignee: Maria Michejda
• Inventors: Michejda, Maria
• Primary Examiner(s): Long; Scott
• Application Number:
  US11/654,737
• Publication Number:
  US 20080171019A1
• Time in Patent Office: 1,483 Days
• Field of Search: None
• US Class Current: 424/93.7
• CPC Class Codes: A01N 1/0221 Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
• CPC Class Codes: A61K 35/48 Reproductive organs

Abstract

The present invention is directed to compositions of fetal hematopoietic stem and progenitor cells and stromal (mesencymal) cells derived from second trimester (16-20 weeks gestation) miscarriages, that are isolated, processed and cryopreserved, and the therapeutic uses of such stem and progenitor cells upon application. Such compositions may be useful for hematopoietic reconstitution and/or replacement in patients with various diseases and metabolic disorders. The invention also relates to methods for collecting, isolating, processing and cryopreserving of the fetal stem and progenitor cells of the invention. Importantly, the invention meets an urgent need in regenerative medicine while at the same time ensures utility of the product compositions because it utilizes fetal materials from second trimester (16-20 weeks of gestation) spontaneously lost pregnancies which are free of moral or ethical burdens.

Claims

1. A method for preparing bone paste from fetal bone chips collected from human fetal tissue from second trimester miscarriages (16-20 weeks of gestation), wherein the fetal bone chips contain hematopoietic stem or progenitor cells and stromal (mesenchymal) cells, said method comprising:

(a) collecting the fetal bone chips;

(b) cryopreserving the fetal bone chips utilizing a non-toxic cryopreservation cocktail consisting of 1 to 2.5% dimethyl sulfoxide, 4-5% human serum albumin and 1-2.5% dextran in RPMI medium; and

(c) thawing the cryopreserved fetal bone chips, such that the stem or progenitor cells are at least 90% viable using said cryopreservation cocktail,

wherein the method further comprises the step of mixing the thawed fetal bone chips, 30-40% by volume, with 10% medium and the balance with agar in an appropriate matrix to produce a bone paste.